DCOY (Decoy Therapeutics) ROCE %: -187.10% (As of Mar. 2026)


DCOY Decoy Therapeutics Inc DCOY
23 GF Score
Price $6.02
! 3 Warning Signs
View Full Analysis

What is Decoy Therapeutics ROCE %?

Decoy Therapeutics DCOY -6.47% 23 ROCE % is -187.10% as of Mar. 2026. GuruFocus rates DCOY with a GF Score™ of 23/100. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Decoy Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -187.10%.

Decoy Therapeutics  (NAS:DCOY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Decoy Therapeutics ROCE % Related Terms

Decoy Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Decoy Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Decoy Therapeutics ROCE % Chart

Decoy Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -42.09 -93.57 -164.55 -168.65 -340.87

Decoy Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -874.25 0.00 -209.48 -713.03 -187.10
DCOY
23GF Score
Decoy Therapeutics Inc DCOY
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Decoy Therapeutics ROCE % Calculation

Decoy Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-12.614/( ( (3.023 - 1.511) + (11.057 - 5.168) )/ 2 )
=-12.614/( (1.512+5.889)/ 2 )
=-12.614/3.7005
=-340.87 %

Decoy Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-9.136/( ( (11.057 - 5.168) + (8.423 - 4.546) )/ 2 )
=-9.136/( ( 5.889 + 3.877 )/ 2 )
=-9.136/4.883
=-187.10 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -187.10% mean?
Decoy Therapeutics (DCOY) has a ROCE % of -187.10% as of Mar. 2026.
Is Decoy Therapeutics' ROCE % too high?
Decoy Therapeutics' current ROCE % is -187.10%. Overall, Decoy Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Decoy Therapeutics' ROCE % compare to ARTL and RNAZ?
Decoy Therapeutics' ROCE % of -187.10% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Decoy Therapeutics's current ROCE % is -187.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Decoy Therapeutics stock overvalued right now?
Decoy Therapeutics (DCOY) has a current ROCE % of -187.10%. The current ROCE % is -187.10%. Decoy Therapeutics' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Decoy Therapeutics (DCOY), the current ROCE % is -187.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Decoy Therapeutics Business Description

Address 2450 Holcombe Boulevard, Suite X, Houston, TX, USA, 77021
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
23GF Score

Get the complete analysis for DCOY

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.02
Price